Drug Trial Radar · NCT04720326
Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
268
Actual
Start
Dec 23, 2020
Primary completion
Jan 25, 2024
Study completion Oct 29, 2026
Sponsor
- Lead sponsor
- Edward GeisslerAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Chiesi Pharmaceuticals GmbH; Excelya
- First posted
- Jan 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Trial participants are randomised within 14 days after liver transplantation surgery in a 1:1 ratio to two alternative treatment arms containing either Envarsus® (test arm) or Advagraf® (comparator arm) as first-line calcineurin inhibitor within a standard-of-care immunosuppressive regimen. Tacrolimus blood trough levels and drug doses are monitored at regular intervals to assess drug bioavailability and the ease and accuracy of achieving the targeted blood concentration range. Dose-normalised trough level (concentration/dose ratio) is measured at 12 weeks post-randomisation as an estimate of tacrolimus bioavailability. It is hypothesised that treatment with Envarsus® will confer a superior (higher) C/D ratio after 12 weeks of therapy owing to the superior bioavailability of this galenic drug formulation (proprietary MeltDose® technology). To test whether an elevated C/D ratio is also associated with improved clinical outcomes, a range of other pharmacokinetic, efficacy and safety variables are evaluated at 10 study visits spanning a period of 3 years.
Conditions
- Prophylaxis Against Liver Transplant Rejection
Interventions
Tacrolimus PillDrug
Envarsus® tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.
Tacrolimus capsuleDrug
Advagraf® capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-normalised blood trough level of tacrolimus (concentration/dose ratio)Time frame: 12 weeks post-randomisation
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
University Hospital Aachen
Aachen, Germany
Charite - University Medicine Berlin
Berlin, Germany
University Hospital Essen
Essen, Germany
University Hospital Frankfurt
Frankfurt, Germany
University Hospital Hamburg Eppendorf
Hamburg, Germany
Hannover Medical School
Hanover, Germany
University Hospital Heidelberg
Heidelberg, Germany
University Hospital Jena
Jena, Germany
University Hospital Schleswig-Holstein - Campus Kiel
Kiel, Germany
University Hospital Leipzig
Leipzig, Germany
University Hospital Magdeburg
Magdeburg, Germany
University Hospital Mainz
Mainz, Germany
University Hospital Muenster
Münster, Germany
University Hospital Regensburg
Regensburg, Germany
University Hospital Tuebingen
Tübingen, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.